2. Search Result
Search Result
Results for "

hBuChE

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-151562
    AChE/BuChE/MAO-B-IN-1

    		Cholinesterase (ChE) Monoamine Oxidase Neurological Disease
    AChE/BuChE/MAO-B-IN-1 (compound 19) is an inhibitor of human acetyl- (hAChE), butyrylcholinesterase (hBuChE) and monoamine oxidase-B (hMAO-B) with IC50s of 4.8 μM, 13.7 μM, and 1.11 μM, respectively. AChE/BuChE/MAO-B-IN-1 also exhibits high affinity to both the σ1 and σ2 receptors with Ki values of 42.8 nM (human σ1 receptor) and 191 nM (rat σ2 receptor), respectively. AChE/BuChE/MAO-B-IN-1 can be used for Alzheimer’s disease research .
    AChE/BuChE/MAO-B-IN-1
  • HY-168563
    BuChE-IN-15

    		Cholinesterase (ChE) FAAH Neurological Disease
    BuChE-IN-15 (compound D12) is a selective BuChE/FAAH dual inhibitor with and show IC50 values of 81 and 400 nM for hBuChE and hFFAH, respectively. BuChE-IN-15 possesses good BBB penetration, and shows neuroprotection.BuChE-IN-15 can be used for study of Alzheimer .
    BuChE-IN-15
  • HY-170691
    hAChE/hBuChE-IN-1

    		Cholinesterase (ChE) Neurological Disease
    hAChE/hBuChE-IN-1 (compound C2) is a dual inhibitor of cholinesterase with IC50 values of 514 nM and 358 nM for hAChE and hBuChE respectively. hAChE/hBuChE-IN-1 has oral activity and improves cognition and spatial memory .
    hAChE/hBuChE-IN-1
  • HY-170417
    hAChE/hBuChE/GSK-3β-IN-1

    		Cholinesterase (ChE) GSK-3 Neurological Disease
    hAChE/hBuChE/GSK-3β-IN-1 (Compound 6c) is a BBB-penetrable and multi-target anti-Alzheimer's disease compound. hAChE/hBuChE/GSK-3β-IN-1 is the inhibitors of hAChE (IC50: 28.88 nM), hBuChE (IC50: 131.90 nM) and GSK-3β (IC50: 51.42 nM). hAChE/hBuChE/GSK-3β-IN-1 is the tau and Aβ protein aggregation inhibitors .
    hAChE/hBuChE/GSK-3β-IN-1
  • HY-155366
    hAChE-IN-6

    		Cholinesterase (ChE) GSK-3 Neurological Disease
    hAChE-IN-6 (compound 51) is a brain penetrant AChE inhibitor with an IC50 of 0.16 μM. hAChE-IN-6 also inhibits hBuChE and GSK3β with IC50 values of 0.69 μM and 0.26 μM, respectively. hAChE-IN-6 inhibits tau protein and Aβ1-42 self-aggregation, and can be used for Alzheimer's disease (AD) research .
    hAChE-IN-6
  • HY-136813
    Multitarget AD inhibitor-1

    		Beta-secretase Amyloid-β Cholinesterase (ChE) Neurological Disease
    Multitarget AD inhibitor-1 is a selective and reversible butyrylcholinesterase (BuChE) inhibitor with IC50s of 7.22 μM and 1.55 μM for hBuChE and eqBuChE (BuChE from equine serum), respectively. Multitarget AD inhibitor-1 inhibits β-secretase (IC50hBACE-1=41.60 μM), amyloid β aggregation (IC50Aβ=3.09 μM), tau aggregation. Multitarget AD inhibitor-1, a diphenylpropylamine derivative, has the potential for multifunctional disease-modifying anti-Alzheimer’s research .
    Multitarget AD inhibitor-1
  • HY-155365
    hAChE-IN-5

    		Cholinesterase (ChE) GSK-3 Amyloid-β Neurological Disease
    hAChE-IN-5 (compound 49) is a potent hAChE and hBuChE inhibitor with IC50 values of 0.17 μM and 0.17 μM, respectively. hAChE-IN-5 shows potent GSK3β inhibition with an IC50 value of 0.21 μM. hAChE-IN-5 is used as tau protein aggregation and Aβ1-42 self-aggregation inhibitor. hAChE-IN-5 can bind virtually with the PAS affecting Aβ aggregation, thus preventing Aβ-dependent neurotoxicity. hAChE-IN-5 can penetrate BBB and has the potential for multi-targeted anti-Alzheimer's agents research .
    hAChE-IN-5
  • HY-157527
    hAChE-IN-7

    		Cholinesterase (ChE) Beta-secretase Neurological Disease
    hAChE-IN-7 (compound 5s) is a mixed inhibitor affecting both the catalytic active site (CAS) and peripheral anionic site (PAS) of hAChE. hAChE-IN-7 displays the balanced inhibitory effect on hAChE (IC50=69.8 nM) and hBuChE (IC50=68.0 nM), and exhibits inhibitory activity against β-secretase-1 (BACE-1) (IC50=3.6 μM). hAChE-IN-7 has the potential for Alzheimer's disease (AD) research .
    hAChE-IN-7
  • HY-W042583
    Deoxynojirimycin tetrabenzyl ether

    		Cholinesterase (ChE) Neurological Disease
    Deoxynojirimycin tetrabenzyl ether (compound 2) is an inhibitor of hBuChE with IC50 value of 2.0 μM .
    Deoxynojirimycin tetrabenzyl ether
  • HY-152632
    BuChE-IN-7

    		Cholinesterase (ChE) Neurological Disease
    BuChE-IN-7 is a highly selective inhibitor of hBuChe and eqBuChE with IC50 values of 40 nM, 80 nM respectively. BuChE-IN-7 can promote cognitive with blood-brain penetration and improves situational and phobic memory, showing preference for new things .
    BuChE-IN-7
  • HY-146251
    BuChE-IN-6

    		Cholinesterase (ChE) Amyloid-β Neurological Disease
    BuChE-IN-6 (compound 1b) is a potent and selective BuChE (butyrylcholinesterase) inhibitor, with IC50 values of 0.46 and 0.51 μM for eqBuChE and hBuChE, respectively. BuChE-IN-6 also inhibits Aβ42 self-aggregation .
    BuChE-IN-6
  • HY-173486
    BuChE-IN-21

    		Cholinesterase (ChE) Neurological Disease Inflammation/Immunology
    BuChE-IN-21 (compound SXF3) is a potent and selective BuChE inhibitor. BuChE-IN-21 inhibits eqBuChE and hBuChE with IC50s of 0.05 and 0.04 μM, respectively. BuChE-IN-21 has high anti-inflammatory activity .
    BuChE-IN-21
  • HY-172782
    BuChE-IN-20

    		Cholinesterase (ChE) Amyloid-β Interleukin Related Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) Neurological Disease Inflammation/Immunology
    BuChE-IN-20 is a selective butyrylcholinesterase (hBuChE) inhibitor (IC50 = 0.13 μM) with BBB permeability. BuChE-IN-20 is a L-Tryptophan derivative. BuChE-IN-20 possesses neuroprotective properties by inhibiting the production of nitric oxide (NO) and lowering the levels of ROS. BuChE-IN-20 is proficient in inhibiting the self-aggregation of amyloid-beta (Aβ) peptides. BuChE-IN-20 can be used in research for Alzheimer’s disease .
    BuChE-IN-20
  • HY-163746
    BuChE-IN-11

    		Cholinesterase (ChE) Neurological Disease
    BuChE-IN-11 (Compound 3b-1) is an selective BuChE inhibitor with an IC50 of 0.44 μM for hBuChE. BuChE-IN-11 has high blood-brain barrier permeability and exhibits strong antioxidant activity due to its free radical scavenging properties. BuChE-IN-11 interacts with the choline binding site, acetyl binding site, and peripheral anionic site, exhibiting submicromolar BuChE inhibitory activity and preventing β-amyloid (Aβ) self-aggregation. BuChE-IN-11 holds promise for research in the field of Alzheimer's disease .
    BuChE-IN-11
  • HY-181865
    BuChE-IN-22

    		Cholinesterase (ChE) Drug Intermediate Neurological Disease
    BuChE-IN-22 is a pseudo-irreversible butyrylcholinesterase (BuChE) inhibitor, with IC50 values of 4 nM and 157 nM against hBuChE and hAChE, respectively. It also acts as a prodrug of 7-hydroxysertraline. BuChE-IN-22 releases 7-hydroxysertraline during BuChE inhibition. BuChE-IN-22 completely reverses Aβ25-35-induced short-term and long-term memory impairments in a mouse model of Alzheimer's disease. BuChE-IN-22 can be used in research related to Alzheimer's disease .
    BuChE-IN-22
  • HY-182001
    Multi-kinase-IN-13

    		Cholinesterase (ChE) GSK-3 Neurological Disease
    Multi-kinase-IN-13 (Compound 10F) is an inhibitor of AChE, BuChE, and GSK-3β, with an IC50 of 3 nM against hAChE, 303 nM against hBuChE, and 7.58 nM against GSK-3β. Multi-kinase-IN-13 exhibits in vitro iron chelating activity. AChE-IN-110 can be used in the research of Alzheimer's disease .
    Multi-kinase-IN-13
  • HY-180892
    Multi-kinase-IN-10

    		Calcium Channel Cholinesterase (ChE) Neurological Disease
    Multi-kinase-IN-10 (Compound IIIk) is a multi-kinase inhibitor. Multi-kinase-IN-10 exhibits significant calcium channel blocking activity, with its IC50 being 26.67 μM. Multi-kinase-IN-10 is a potent dual cholinesterase inhibitor, with its IC50 values for hAChE and hBuChE being 0.304 μM and 1.033 μM respectively. Multi-kinase-IN-10 has antioxidant and neuroprotective activities, and shows significant anti-amnesia activity. Multi-kinase-IN-10 can be used for research on Alzheimer's disease .
    Multi-kinase-IN-10
  • HY-180891
    Multitarget AD-IN-4

    		Cholinesterase (ChE) Calcium Channel Neurological Disease
    Multitarget AD-IN-4 (compound IIIj) is a multitarget-directed ligand (MTDL), with the ability to simultaneously inhibit ChE enzymes (EeAChE IC50 = 0.157 μM, eqBuChE IC50 = 0.147 μM, hAChE IC50 = 1.551 μM, hBuChE IC50 = 2.152 μM), exhibit antioxidant activity, provide neuroprotection, and inhibit calcium channels (Ca 2+ channel blockade: IC50 = 30.59 μM). Multitarget AD-IN-4 reverses Scopolamine (HY-N0296)-induced amnesia in a mouse model. Multitarget AD-IN-4 can be used for Alzheimer’s disease (AD) research .
    Multitarget AD-IN-4
  • HY-183352
    BuChE-IN-23

    		Cholinesterase (ChE) Toll-like Receptor (TLR) p38 MAPK Interleukin Related Complement System Neurological Disease
    BuChE-IN-23 is an orally active, blood-brain barrier permeable butyrylcholinesterase (eqBuChE) inhibitor with an IC50 of 15.59 μM and a Ki of 29.33 μM. BuChE-IN-23 exhibits an IC50 of 38.65 μM against hBuChE and shows selectivity for butyrylcholinesterase over acetylcholinesterase. BuChE-IN-23 inhibits LPS (HY-D1056)-induced nitric oxide production, attenuates hippocampal glial cell activation and neuroinflammation, suppresses the TLR4/p38 MAPK signaling pathway, and regulates the IL-1β/C3-mediated microglia-astrocyte inflammatory axis. BuChE-IN-23 can be used for the research of Alzheimer's disease .
    BuChE-IN-23

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: